Table 4.
Follow-up outcomes
| Outcome | Bevacizumab group (n = 7) |
Laser group (n = 9) |
Difference in medians (95% CI) | P value |
|---|---|---|---|---|
|
|
||||
| Median (range) | Median (range) | |||
| Corrected age at follow-up, months | 21.2 (18.1–28.5) | 19.1 (18.0–21.4) | 1.9 (−0.1 to 9.0) | 0.10 |
| Weigh t percentile for age | 18 (0 – 56) | 7 (0 – 39) | 14 (− 7 to 49) | 0.27 |
| Length percentile for age | 8 (3–83)a | 29 (2–73) | −11 (−54 to 16) | 0.39 |
| Head circumference percentile for age | 0 (0–77)a | 8 (0–77) | −2 (−24 to 47) | 0.46 |
| Cognitive composite score | 85 (60 – 100) | 65 (55 – 100) | 10 (− 5 to 30) | 0.06 |
| Language composite score | 89 (59–91) | 71 (47–106) | 12 (−15 to 30) | 0.18 |
| Motor composite score | 79 (58 – 100) | 70 (55 – 100)b | 8 (−15 to 33) | 0.22 |
|
|
||||
| No. (%) | No. (%) | RR (95% CI) | ||
|
|
||||
| On oxygen at follow-up | 1 (14)b | 0 | NA | 0.40 |
| Gross motor function level | Normal/n 1.61 (0.67 to 3.83) |
0.85 | ||
| Normal | 5 (71) | 4 (44) | ||
| 1 | 0 | 2 (22) | ||
| 2 | 1 (14) | 1 (11) | ||
| 3 | 0 | 1 (11) | ||
| 4 | 1 (14) | 1 (11) | ||
| 5 | 0 | 0 | ||
| Cerebral palsy | 2 (28) | 2 (22) | 1.29 (0.24 to 6.99) | 1.00 |
CI, confidence interval; RR, relative risk.
a
2 missing.
b
1 missing.